DLX-2323

N/A

Report date: 2022/01/17 17:59:18

Base Information

Drug NameDLX-2323
Drug Alias NameDLX-2323
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDelenex Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesDelarrivo Inc
Inactive CompaniesN/A
Active IndicationsInflammation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A